Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

NCT01719861 is registered in ClinicalTrials.gov with Joel Neal as lead sponsor.

NCT NCT01719861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01719861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Lead sponsor
Joel Neal
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2012
Completion date
May 31, 2015
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors, small cell lung cancer (sclc)